Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Repligen Corp (RGEN) -- Ignore unavailable to you. Want to Upgrade?

To: David Wise who wrote (79)	7/23/1998 8:56:00 AM
From: E'Lane	Respond to of 395

Repligen Sues Bristol-Myers Squibb Over Immune-System Discovery Boston, July 21 (Bloomberg) -- Repligen Corp. is suing Bristol-Myers Squibb Co. for not including the co-inventor of a method to regulate the body's immune system in a patent, and violating Repligen's rights to the discovery. The suit filed against the world's largest cancer-drug maker in federal court in Boston Friday seeks unspecified damages and asks the court to declare Dr. Craig Thompson a co-inventor. Repligen claims Bristol-Myers misused trade secrets in not crediting Thompson, who licensed his rights to the invention to Repligen. Thompson conceived of the idea of using a protein called CTLA4 to regulate the body's immune system and told his research colleagues at Bristol-Myers, the suit said. Bristol-Myers researched the idea, then won a patent covering the protein's use without mentioning Thompson's contribution, according to the court filing. ''Repligen was never able to form a partnership for clinical development of (the substance) with any one of a number of pharmaceutical companies which expressed interest in the technology,'' the company said in court papers. New-York based Bristol-Myers also makes Clairol hair products and Excedrin painkiller. A company official had no immediate comment. Needham, Massachusetts-based Repligen is developing treatments for cancer and eye diseases. Its primary focus is developing inhibitors of angiogenesis -- or new blood vessel growth -- to stop the growth of tumors. Its shares rose 1/32 to 1 7/16. Bristol-Myers fell 5 7/8 to 119 15/16. 17:25:53 07/21/1998 Any redistribution of Bloomberg content, including by framing or similiar means, is expressly prohibited without the prior written consent of Bloomberg L.P. Any reference to the material must be properly attributed to Bloomberg News. The information herein was obtained from sources which Bloomberg L.P. and its suppliers believe reliable, but they do not guarantee its accuracy. Neither the information, nor any opinion expressed, constitutes a solicitation of the purchase or sale of any securities or commodities.(C) Copyright 1998 Bloomberg L.P. BLOOMBERG, Bloomberg News, Bloomberg Financial Markets, Bloomberg Television, Bloomberg News Radio are trademarks, tradenames and service marks of Bloomberg L.P.